China Healthcare Weekly (Mar.15)- New Policy of Innovative Drug, TCM Formula Granules, Xingqi Pharma
New policy of innovative drug is a big deal. We've reasons to start being optimistic.The market pattern of TCM formula granules will face...
320 Views
Lepu Biopharma (乐普生物科技) IPO: Sentiment Cooled Down
Downsized deal amid cooled sentiment for Chapter 18A, we think the valuation of Lepu Biopharm is not attractive for investors.
275 Views
Zhaoke Ophthalmic (兆科眼科) IPO Trading: Strong Cornerstone Doesn't Save the Deal
We re-iterate our differentiated bearish view with the deal. The deal received lukewarm interests from retail and institutional investors. We would...
349 Views
Zhaoke Opthalmology IPO Valuation: Overpriced
Some of the company’s drug candidates have the potential to become market-leading products, however, Zhaoke does not have any prior experience in...
311 Views
ECM Weekly (18th April 2021) - ByteDance Zhaoke, We Doctor, Medlive, Bio-Thera, Grab, Ngern Tid Lor
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
325 Views